CMCT Q2 2026 Report Reinforces Distressed Profile; Reverse Splits Persist

What happened

CMCT released its Q2 2026 results, but the press release is light on financial detail, noting only the two reverse stock splits in March and April 2026. The prior master report already flagged severe distress: net debt/EBITDA of 12.2x, interest coverage of 0.25x, and persistent net losses across 2024-2025. The repeated reverse splits indicate the share price remained below Nasdaq compliance levels and management opted for cosmetic fixes rather than fundamental repair. Stock-settled preferred redemptions likely continued, further diluting common holders. Overall, the news aligns with the existing strong sell thesis, as no evidence of operational improvement or balance sheet repair is provided.

Implication

Common equity remains a deeply out-of-the-money option on successful refinancing and portfolio repositioning. The two 2026 reverse splits confirm the stock's low price and management's reliance on share-count engineering, which worsens per-share economics. With roughly $366 million of debt maturing in 2026-2027, refinancing risks are acute and likely to come with punitive terms that erode residual value. Investors should track interest coverage and office occupancy closely; any further deterioration would compound the impairment risk. Until net debt/EBITDA declines materially and interest coverage exceeds 1.5x, the downside for common holders—including potential wipeout—dominates the risk-reward.

Thesis delta

No shift from the strong sell stance; the Q2 2026 reverse splits reinforce the existing thesis of ongoing share price distress and likely dilution. The press release offers no evidence of improved fundamentals or successful balance sheet actions. The investment case remains highly speculative with significant downside risk.